


Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath

The University of Dublin



MSc in ImmunoTherapeutics (1 Year Full-Time)

The MSc in ImmunoTherapeutics is for scientists wishing to pursue careers in the therapeutics industry and related fields.

Course content

- Students will learn about: the immune system in cancer, autoimmunity, infection and neurodegeneration.
- How exciting technologies of DNA/RNA vaccines, antibody, stem cell and, CAR T-cell therapies, and immune-checkpoint blockade are revolutionising the treatment of life-threatening and debilitating diseases.
- Skills in business development, innovation, entrepreneurship and communication in the Trinity Business School and bioprocessing in the National Institute for Bioprocessing, Research and Training (NIBRT) at their state-of-the-art facility.

Is this course for me?

The programme is aimed at science, medical, veterinary and engineering graduates as well as employees in the pharmaceutical/ biotech sector who wish to work in high level jobs in the biopharma industry or continue further biomedical research.

Key fact

This MSc programme provides a six-month project with industry.

Course structure

90 credits taught masters

60 credits taught modules

30 credits project placement

Modules:

- Fundamental Immunology
- Advanced ImmunoTechnologies
- ImmunoTherapeutics
- Research in Action

- Bioprocessing
- Entrepreneurial Action
- Computational Immunology
- Innovation and Drug Development



Ranked in the **Top 100** universities in the world for Biomedical Sciences (QS 2019)





Trinity is ranked **104th** in the world (QS World University Rankings 2019)



Ranked as Ireland's leading University (QS World University Rankings 2019)

Ranked 1st in Ireland for Graduate Employability Rate & Alumni Outcomes (05 2019)

Why study

ImmunoTherapeutics at Trinity?

Global leader

Trinity is a member of the League of European Research Universities (LERU) and has three academics in the top 1% of immunology researchers worldwide.

World class facilities and research collaborations

The MSc will be housed in the stateof-the-art Trinity Biomedical Sciences Institute with participitation from the Schools of Biochemistry & Immunology, Medicine, Chemistry, Bioengineering, Pharmacy.

Employability

The world's top 10 largest biopharma companies operate in Ireland with employment in this sector growing fivefold over the last 30 years with an estimated 8,400 new roles to be created by 2020.

Career opportunities

This new MSc in ImmunoTherapeutics has been designed in collaboration with the biopharma industry in Ireland and industry partners committed to teaching and projects include Avectas Ltd, Pfizer, Janssen Pharmaceutica, Fountain Healthcare, NIBRT, GlaxoSmithKline, Iontas Antibody Discovery, Galactica Biotech, Merrion Fertility, HiTech Health, Solvotrin.

Apply now

Early application is advised: www.tcd.ie/masters_immunotherapeutics/apply

Fees

Tuition fee information is available at: www.tcd.ie/academicregistry/fees-and-payments

Contact us

Cliona O'Farrelly PhD, Professor of Comparative Immunology, Course Director Jerrard Hayes PhD, Assistant Professor of Glycobiology, Course Co-ordinator

Email: immunotherapeutics.msc@tcd.ie

www.tcd.ie/biochemistry/postgraduate/masters_immunotherapeutics



Studying immunotherapeutics is a great opportunity to further understand the possibilities of harnessing our bodies own capabilities to treat disease. In the MSc in Immunology we developed a deeper understanding of immunology, medicine and product development and this new course is exciting as it not only touches upon academic research, but also introduces students to industry."

Sara Patti (USA) MSc Immunology (Trinity College Dublin)



▲ Increased understanding of the immune system has led to breakthrough immunotherapies that promise to be game changers for the way many diseases are treated. At such an exciting time for these new approaches, this M.Sc. in Immunotherapeutics will provide an excellent opportunity for students to learn about the development, manufacturing and ultimately the full potential of these new therapeutics."

Shirley O'Dea, Co-founder and Chief Scientific Officer, Avectas Ltd.

